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Abstract 
Objective: The objective of this selective EBM review is to determine whether or not “Is 
amitriptyline effective in reducing headache days in pediatric patients with migraines and 
chronic headaches compared to topiramate, propranolol, or no treatment?” 
Study design: Systematic review of two randomized control trials (RCTs) and one case series 
published in peer-reviewed journals in English after 2007. 
Data Sources: Two RCTs and one case series were found using PubMed.  
Outcome(s) Measured: Headache frequency was measured using a headache diary or calendar. 
A secondary objective included headache severity that was measured using a ten-point scale or 
the Pediatric Migraine Disability Assessment (PedMIDAS). 
Results: Powers et al. found that headache frequency did not vary significantly between 
amitriptyline, topiramate, or placebo.2 It was also recorded that there was no significant variation 
among reduction in scores on the PedMIDAS.2 Eidlitz-Markus et al. stated that this trial showed 
no significant difference between amitriptyline and propranolol(p-value=0.8).4 Sezer et al. found 
that 31% of patients in the topiramate group and 28% of patients in the amitriptyline group 
“reported freedom from headache.”5 It was also recorded that the severity of headaches also 
decreased 4.5 points on a visual analog scale in both treatment groups.  
Conclusions: Amitriptyline in these three trials is less effective in reducing the frequency of 
chronic headaches and migraines when compared to topiramate, propranolol, or a placebo.2,4,5 
These results could be affected by subjectivity, drug adherence, or misunderstanding between 
younger subjects and their parents. The safety of amitriptyline should always be in question 
because the FDA warns that antidepressants can cause suicidal thoughts or actions in children 
under eighteen years old.  
Key Words: pediatric, migraine, headache, amitriptyline 
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Introduction  
Migraines are primary throbbing headaches of moderate or severe intensity that are 
worsened by activity and associated with photophobia and/or phonophobia. These can be 
accompanied by vomiting and abdominal pain. The pathophysiology is unclear. The most studied 
and most recent theory is migraines are caused by cortical spreading depolarization across the 
brain which can be associated with the aura before a migraine. This depolarization leads to 
trigeminovascular system activation, causing increased activity in pain pathways. Migraines can 
affect patients of all ages but studies show most children with migraines will have them 
lifelong.1,2 They are more common in males in younger populations but more common in 
females overall.1,2 Less than 25% of boys and 15% of girls have migraines before reaching age 
fourteen.1 Altogether, more than 6 million children in the U.S. have migraines.2,3 These costs for 
all patients of all ages are approximately $36 billion.2 Unfortunately, there is no way, other than 
clinically, to diagnose migraines in any population. Acute treatment of migraines includes 
analgesics (such as acetaminophen, ibuprofen, and naproxen), migraine-specific medications 
commonly called “triptans” (such as sumatriptans, almotriptan, zolmitriptan or rizatriptan), or IV 
dihydroergotamine. Preventative treatment of migraines includes antiepileptics (such as 
topiramate or valproic acid), antihypertensives (such as flunarizine or propranolol), 
antihistamines (such as cyproheptadine), and antidepressants (such as amitriptyline or 
nortriptyline).  
Chronic headaches are primary headaches that occur fifteen or more days each month for 
three or more consecutive months. These headaches have different characteristics than 
migraines. Chronic headaches are not throbbing and are not associated with photophobia or 
phonophobia but they can be just as incapacitating as migraines. There may be overlap in 
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patients with chronic headaches who also have a history of migraines.5 Both types of headaches 
affect school performance but migraines alone are associated with higher deficiencies and 
abscences.3,4 Studies and practitioners use the Pediatric Migraine Disability Assessment Scale 
(PedMIDAS) to measure the debilitating effects of headaches on “school, home, play, and social 
activities,”2  
There is no single pharmacologic therapy suggested for the prevention of chronic 
headaches or migraines in patients under eighteen. As with most diagnoses, pediatric patients are 
tried on lower doses of treatments shown to provide relief in adults. These treatments are 
complicated even more by the dosing difference in patients under twelve. Children older than 
twelve should be treated with adult dosing. Most pediatric treatment strategies are based on 
studies in adults. Amitriptyline is an oral tricyclic antidepressant used frequently for migraine 
and chronic headache prevention in adults. Children older than twelve can take adult dosing but 
younger children should take 1mg/kg/day (max 200mg/day). Amitriptyline inhibits serotonin 
reuptake throughout the central nervous system. The theory behind this preventative strategy is 
to prevent the low serotonin conditions that lead to an increase in pain receptor pathways during 
trigeminovascular activation.  
This paper evaluates two double-blind, RCTs and one case series comparing the efficacy 
of amitriptyline with either topiramate, propranolol, or no treatment for reducing headache days 
in pediatric patients diagnosed with chronic headaches or migraines. 
Objective 
The objective of this selective EBM review is to determine whether or not “Is 
amitriptyline effective in reducing headache days in pediatric patients with migraines and 
chronic headaches compared to topiramate, propranolol, or no treatment?” 
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Methods  
The author concluded all research by reviewing studies that analyzed the effectiveness of 
amitriptyline. Two double-blinded RCTs and one case series surrounding female and male 
participants younger than nineteen diagnosed with chronic headaches or migraines were chosen 
for this selective review.  
Amitriptyline was compared to different interventions, such as topiramate, propranolol, 
or no treatment, in efficacy of reducing the frequency of headache days during each specified 
trial period. Trial periods varied from 4 months to 24 weeks.2,5 The frequency of headache days 
throughout each study was measured using a headache calendar or diary. A secondary goal was 
to reduce headache severity. This was recorded via a ten-point scale or the PedMIDAS.  
All articles were found via PubMed using the key words: pediatric, migraine, headache, 
and amitriptyline. The author conducted all research for this review and carefully selected 
articles that were both relevant and patient-oriented. The inclusion criteria for this review 
encompassed articles that were primary research studies published between 2007 and the present, 
all subjects were diagnosed with chronic headaches or migraines, and one trial group must be 
treated with amitriptyline. Exclusion criteria for this review omitted articles that were not in 
English, not peer-reviewed, and articles with subjects older than eighteen. Statistics were 
reported using p-values and CI. After narrowing down studies with inclusion and exclusion 
criteria, the author evaluated the relevance and validity of all articles.  
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Table 1: Demographics of included studies 
Study Type  #of 
Pts 
Age 
(yrs) 
Inclusion criteria Exclusion criteria W/D Interventions 
Powers 
(2017)2 
Double 
blinded 
RCT 
361 8-17 Diagnosis of migraine 
with/without aura or 
chronic migraine 
without continuous 
headache as defined 
by the International 
Classification of 
Headache Disorders, 
2nd edition 
A score on the 
PedMIDAS from 11 
to 139 
A headache 
frequency of >4 days 
from a prospective 
headache diary over a 
baseline period of 28 
days 
No exclusion criteria 
listed 
64 Amitriptyline 
1mg/kg/day 
PO 
 
Topiramate 
2mg/kg/day 
PO 
 
Placebo 
 
Eidlitz-
Markus 
(2012)4 
Case 
series 
118 4-18 Pediatric patients 
ages 4.4 to 18 with 
either chronic or 
episodic migraine 
headaches making 
non-pharmacological 
lifestyle changes 
 
Inability to verbally 
communicate pain  
Failure to adhere to 
full instructions for 
treatment 
Failure to maintain 
regular follow-up 
Overusing prescribed 
medication 
Parental refusal of 
pharmacologic 
treatment 
N/a Amitriptyline 
10-25 mg/day 
PO QHS 
 
Propranolol 5-
80 mg/day PO 
BID 
 
Sezer 
(2013)5 
Double 
blinded 
RCT 
60 12-16 Pediatric patients 
with chronic daily 
headache including 
chronic migraines 
Symptoms of 
increased intracranial 
pressure, neurological 
abnormalities as 
revealed by clinical 
examination or brain 
MRI 
The presence of 
systemic diseases and 
major psychiatric 
disorders (depression) 
The current use of 
high-dose analgesics  
Previously used 
amitriptyline or 
topiramate 
3 Amitriptyline 
0.5 mg/kg PO 
 
Topiramate 
100 mg/day 
PO 
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Outcomes measured  
The frequency of headache days in all three studies was recorded by way of individual 
calendar or diary entries by subjects or their parents. An outcome of greater than 50% reduction 
in headache frequency was presented in all studies and is seen in Table 2. The secondary 
objective noted in two studies was to reduce headache baseline severity. Powers et al. measured 
severity using the PedMIDAS.2 Sezer et al. measured headache severity using a ten-point visual 
analog scale (VAS) in which 10 indicates most severe and 1 indicates least severe.5 
Results  
 This review compares the efficacy of amitriptyline to similar migraine prevention 
methods in three different studies. Powers et al. compared 1mg/kg/d of amitriptyline to 2mg/kg/d 
of topiramate or placebo.2 Patients were included in the study if they had a previous diagnosis of 
any type of migraine with or without aura except continuous migraine as defined by the 
International Classification of Headache Disorders, 2nd edition, a PedMIDAS score 11-139 or a 
headache frequency more than four days during the baseline period (twenty-eight days) before 
the study.2 In this twenty-four week trial the reduction in headache days from baseline to the end 
of the trial was -6.7 days (95% CI, -7.9 to -5.5) with amitriptyline and -6.7 days (95% CI, -7.6 to-
5.7) with topiramate. The placebo had very similar results causing an early end to the trial due to 
the ineffectiveness of the trial’s pharmacologic interventions (Table 2).2 Reduction of headache 
severity was calculated by comparing the PedMIDAS score during the baseline period and the 
post-treatment score. There was no significant difference in reduction of disability scores when 
comparing any two treatment methods (Table 3).2   
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Table 2: Greater than 50% reduction in headache frequency 
Study  Amitriptyline Comparison group(s) 
Powers (2017)2 52% 55% topiramate 
61% placebo 
Eidlitz-Markus (2012)4 82.2%  85% propranolol 
Sezer (2013)5 55% 61% topiramate 
Table 3: PedMIDAS scores2  
 Treatment 
comparison   
Difference in score pre-treatment to post-
treatment 
P-value  
Amitriptyline Topiramate 4.5 0.10 
Placebo -0.4 0.91 
Topiramate Placebo -4.8 0.13 
 Eidlitz-Markus et al. compared 0.266-0.4mg/kg/d of amitriptyline to 0.47-0.81mg/kg/d of 
propranolol.4 Patients were included in the study if they were under age eighteen, were diagnosed 
chronic or episodic migraine headaches, and were making “non-pharmacologic lifestyle 
changes.”4 Children were excluded from the study if they were unable to verbally express their 
pain to parents or staff, if caregivers or subjects were unable to follow instructions for treatment 
or follow-up, if subjects overused treatment methods of any type of medication, or if parents 
refused treatments for the subjects.4 The results of this trial showed no significant difference 
between the different treatment options (p-value=0.8) (Table 2).4 The dosage of each medication 
was titrated throughout the trial to attempt to increase drug effectiveness. After subjects’ dosage 
of propranolol had reached 0.81mg/kg/d without efficacy, treatment was switched from 
propranolol to amitriptyline.4 In the propranolol treatment group, 72% of subjects without aura 
saw 75% or more decrease in headache frequency as compared to 28% of subjects with aura (p-
value=0.02).4 The same association was not seen in the amitriptyline group.  
 Sezer et al. compared 0.5mg/kg of amitriptyline to 100mg/d of topiramate.5 Children 
were selected for this trial if they were age 12-16 with chronic daily headache.5 This 
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encompasses patients with chronic migraine. Sezer et al. stated children were excluded from the 
trial if they had “symptoms of increased intracranial pressure, neurological abnormalities as 
revealed by clinical examination or brain MRI, the presence of systemic diseases, major 
psychiatric disorders including depression, and the current use of high-dose analgesics or 
previously used amitriptyline or topiramate.”5 This article reports after four months of treatment, 
28% of patients treated with amitriptyline “reported freedom from headache.”5 Which was less 
than the 31% of patients treated with topiramate who reported the same (p-value>0.05).5 The 
severity of headaches decreased 4.5 points on the VAS after treatment for both amitriptyline and 
topiramate (p-value>0.05).5 
 As seen in Table 2, the reduction in headache frequency is evident. In a final analysis, the 
reduction in frequency is slightly higher in comparison groups. According to the numbers needed 
to treat (NNT) in Table 3 for all three articles, patients would see benefits with other trial 
medications or placebos than with amitriptyline. The NNT for each article was below zero. From 
the study by Powers et al. amitriptyline is compared to placebo in Table 3.2  
Table 4: Number Needed to Treat (NNT) or Harm (NNH) 
Study  RRR ARR NNT RRI ARI NNH 
Powers (2017)2 -0.15 -0.09 -11.11-11    
   N/a 0.01 100 
Eidlitz-Markus 
(2012)4 
-0.04 -0.028 -35.7-35    
Sezer (2013)5 -0.10 -0.06 -16.66-16    
 
 The safety of amitriptyline will come into question for all pediatric patients. 
Unfortunately, amitriptyline was associated with significant adverse events in four patients such 
as altered mood, and syncope (Table 4).2 The FDA has always cautioned against using 
antidepressants in patients under eighteen years old for risk of suicidal thoughts or actions.  
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Discussion  
 There are a significant amount of studies covering of the benefits and risks of 
amitriptyline in adult populations.6 Studies in pediatric populations regarding any treatment 
method are scarce. This became a limitation of the author’s searching. Future studies should 
encompass more pediatric double-blind, randomized control trials.  
One limitation of most studies was the lack of investigation into compliance. Only one 
study checked compliance of patients and their parents by testing serum drug levels.2 The 
outcomes of these studies could vary significantly if families were reporting use but were not 
following dosing or other directions.  
Powers et al. concluded the study early due to futility.2 There is a significant amount of 
evidence from the 24 week trial and continuing the study would not have produced new 
information on the benefits or risks of amitriptyline, topiramate, or placebo.2 Powers et al. has 
shown to be very thorough due to its baseline survey over 28 days and the comparison of this 
baseline to the last 28 days of the study. 
Every medication has side effects on the body. Amitriptyline’s primary side effects are 
changes in behavior or thinking, dry mouth, and fatigue. All of these mental and anticholinergic 
side effects were reported in the study by Powers et al.2 It is primarily prescribed for major 
depressive disorder but has many off-label uses in adults. In children, the only uses are for the 
treatment of depression, chronic pain management, and migraine prophylaxis.   
Conclusion 
Tricyclic antidepressants such as amitriptyline is effective in treating adults with chronic 
headaches and migraines but it appears to be ineffective in children.6 Amitriptyline, in all three 
trials, was less effective in reducing the frequency of chronic headaches and migraines when 
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compared to topiramate, propranolol, or a placebo.2,4,5  These outcomes may be affected by the 
subjectivity of results collection. The documentation on headache calendars or diaries was 
recorded at home by pediatric patients or their parents which may have been affected by 
improper documentation. These outcomes may also have been affected by patient drug 
adherence. Fortunately, this was combatted by close follow up during the trials and serum-drug 
level testing by Powers et al. Future studies should include more testing for adherence. Some 
documentation was by parents whose children had limited communication skills.4 These parents 
may have misinterpreted their child’s signs further skewing results of the trial. Further studies 
should be conducted comparing different dosages of amitriptyline due to the variation amongst 
the studies selected for this review.  Overall, more studies are required to decrease the instance 
and severity of migraines and headaches in pediatric populations.
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